From investors' perspective, the prognosis is really good here [in the pharmaceuticals sector]. |
What happened when Warner merged with Pfizer in the end of May is that you will have a much broader portfolio. You will have probably 10 different drugs growing at double-digit rates. One of the advances of this merger is to broaden the focus beyond just the two drugs. |